Locatroll Soft Capsule 0.25 Micrograms (Calcitriol)
Calcitriol 0.25μg
Soft capsule · Prescription medication
GP Therapeutics Korea Co., Ltd.
MFDS item code 200610653 · Notified 2006.07.18
This product's status changed to Approval withdrawn on 2025.09.16. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of bone disorders (renal bone disease, rickets, osteoporosis, etc.) and parathyroid dysfunction
This medication is used for the treatment of secondary hyperparathyroidism and associated metabolic bone disease in patients with chronic kidney failure before dialysis. It also helps improve renal osteodystrophy in patients undergoing hemodialysis. It is also used in the treatment of hypoparathyroidism (post-surgical, idiopathic or pseudo). It is effective for rickets and osteomalacia, particularly vitamin D-dependent rickets and hypophosphatemic vitamin D-resistant rickets. Furthermore, it is used for the management of osteoporosis. In summary, it is effectively used for various bone-related conditions such as chronic kidney failure, hypoparathyroidism, rickets, osteomalacia, and osteoporosis.
The optimal daily dose of this medicine should be carefully determined for each patient based on serum calcium levels. Start treatment at the lowest possible dose and do not increase the dose without close monitoring of serum calcium. ○ Patients before the dialysis stage: The adult dose is 0.25 ㎍ of calcitriol daily and may be increased to 0.5 ㎍ daily if necessary. ○ Renal osteodystrophy (dialysis patients): The initial daily dose is 0.25 ㎍ of this medicine. Patients with serum calcium levels in the normal range or slightly below normal should receive 0.25 ㎍ every other day. If there is not an adequate response in biochemical test results and clinical symptoms, increase the dose by 0.25 ㎍ daily at intervals of 2 ~ 4 weeks. During this period, serum calcium levels should be measured at least twice weekly. Most patients respond to doses of 0.5 ~ 1.0 ㎍ daily. This medicine improves calcium absorption from the gastrointestinal tract, so some patients taking it may be maintained on a lower calcium intake. In patients prone to hypercalcemia, a small amount of calcium may be sufficient, or calcium supplementation may not be needed at all. ○ Osteoporosis: Administer 0.25 ㎍ of this medicine twice daily. During dose stabilization, serum calcium levels should be measured at least twice weekly. If hypercalcemia is observed, discontinue treatment until serum calcium levels return to normal. Because this medicine increases calcium absorption in postmenopausal patients with osteoporosis, calcium supplementation may not be necessary. ○ Hypoparathyroidism and rickets/osteomalacia: The recommended initial dose is 0.25 ㎍ of this medicine each morning. If there is not an adequate response in biochemical test results and clinical symptoms, increase the dose at intervals of 2 ~ 4 weeks. During dose determination, serum calcium levels should be measured at least twice weekly. Malabsorption sometimes occurs in patients with hypoparathyroidism, so higher doses may be necessary. ○ General information: After the optimal dose of this medicine has been determined, serum calcium levels should be measured once monthly. Blood samples for serum calcium measurement should be collected without a tourniquet. If serum calcium rises by 1 mg/dL (250 μmol/L) above the normal range of 9 ~ 11 mg/dL (2,250 ~ 2,750 μmol/L), or serum creatinine rises to 120 μmol/L or higher, promptly reduce the dose sufficiently or discontinue treatment until serum calcium returns to normal. Discontinuing supplemental calcium is also effective for rapidly normalizing serum calcium. Carefully consider reducing dietary calcium intake as well. During hypercalcemia, serum calcium and phosphorus levels should be measured daily. Once levels return to normal, continue treatment at a dose 0.25 ㎍ lower per day than the previous dose.
○ Patients before the dialysis stage, children aged 36 months or older: The dose is 0.25 ㎍ of calcitriol daily and may be increased to 0.5 ㎍ daily if necessary. ○ Patients before the dialysis stage, children under 36 months: The recommended initial dose is 10 ~ 15 ng per kg of body weight daily.
This medication should not be used in patients with diseases related to hypercalcemia or hypercalciuria. Patients allergic to this medication or its components should also avoid administration. Care should be taken in patients who are pregnant, breastfeeding, children under 36 months, or have a history of kidney stones. This medication is an active form of vitamin D, and overdose may lead to elevated serum calcium levels, resulting in various side effects. Therefore, during the use of this medication, serum calcium levels should be regularly checked to ensure they remain within normal range. Calcium intake should also be monitored to avoid exceeding the recommended daily amount, and any calcium supplements or dietary advice should be followed as per the physician's instructions. This medication may increase the risk of hypercalcemia when used concurrently with other vitamin D preparations or calcium-containing medications, so concurrent use should be avoided. Extra caution is needed when taken in combination with diuretics, digitalis preparations, and steroids. If pregnant or breastfeeding, careful consideration should be given to the impact of this medication on the fetus or newborn and should only be used after consulting a physician. Elderly patients may have reduced renal and liver function, so dosage should be adjusted, and side effects should be monitored closely. Overdose may cause symptoms such as vomiting, headache, anorexia, constipation, and in severe cases, to seek appropriate treatment at a medical facility. This medication should be stored in a cool place, away from light and moisture, and securely out of reach of children.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container that protects it from air, light, and moisture. Additionally, it is important to keep it in a cool place below 25 degrees Celsius to maintain its effectiveness.
Orange on top and white on the bottom, oval soft capsule
30 capsules (10 capsules/PTP packaging x 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Calcitriol 0.25μg
Soft capsule · Prescription medication
GP Therapeutics Korea Co., Ltd.

Calcitriol 0.25μg
Soft capsule · Prescription medication
Yuyu Pharmaceutical Co., Ltd.

Calcitriol 0.25μg
Soft capsule · Prescription medication
Korea PMG Pharmaceutical Co., Ltd.

Calcitriol 0.25μg
Soft capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.

Calcitriol 0.25μg
Soft capsule · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Calcitriol 1μg
Injections · Prescription medication
Albozen Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.